NASDAQ:ODTX Odyssey Therapeutics Q2 2026 Earnings Report $22.65 +0.21 (+0.94%) As of 11:03 AM Eastern ProfileEarnings HistoryForecast Odyssey Therapeutics EPS ResultsActual EPS-$1.74Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOdyssey Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOdyssey Therapeutics Announcement DetailsQuarterQ2 2026Date8/5/2026TimeBefore Market OpensConference Call DateTuesday, August 4, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Odyssey Therapeutics Earnings HeadlinesOdyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation ForumSeptember 16, 2026 | globenewswire.comOdyssey Therapeutics (ODTX) Banks Two More Years As Trials MultiplySeptember 13, 2026 | insidermonkey.comThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story.September 30 at 1:00 AM | Stansberry Research (Ad)Odyssey Therapeutics to Participate in Upcoming Investor ConferencesAugust 26, 2026 | globenewswire.comOdyssey Therapeutics Inc.August 18, 2026 | marketwatch.comOdyssey Therapeutics: Q2 Earnings SnapshotAugust 6, 2026 | chron.comSee More Odyssey Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Odyssey Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Odyssey Therapeutics and other key companies, straight to your email. Email Address About Odyssey TherapeuticsOdyssey Therapeutics (NASDAQ:ODTX) is a biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, structural biology, medicinal chemistry and other drug-discovery technologies to identify therapies designed to target specific disease mechanisms. Odyssey’s research programs are centered on small-molecule therapeutics intended to modulate immune pathways and address conditions with significant unmet medical needs. Its development activities span immunology and oncology, with programs progressing through preclinical and clinical research as the company evaluates potential treatments for patients in these areas. Odyssey Therapeutics was founded in 2021 and is based in the United States. Gary Glick, who previously helped establish Nimbus Therapeutics, is the company’s founder and chief executive officer. The company’s work is primarily directed toward advancing internally discovered drug candidates through development and potential commercialization.View Odyssey Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundBernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
